SPCC1442.02 Antibody

What is SPCC1442.02 Antibody and what are its fundamental properties?

SPCC1442.02 Antibody (product code CSB-PA748487XA01SXV) is a rabbit-derived polyclonal antibody specifically designed to target the SPCC1442.02 protein expressed in Schizosaccharomyces pombe (strain 972/ATCC 24843), commonly known as fission yeast. The antibody is raised against a recombinant SPCC1442.02 protein immunogen and purified using antigen affinity chromatography methods to ensure high specificity .

The antibody is supplied in liquid form with a concentration of 1 mg/ml in a storage buffer containing preservative (0.03% Proclin 300) and stabilizers (50% Glycerol, 0.01M PBS, pH 7.4). As a polyclonal IgG antibody, it recognizes multiple epitopes on the target protein, which can provide enhanced detection sensitivity compared to monoclonal alternatives in certain experimental contexts .

What validated applications can SPCC1442.02 Antibody be used for?

SPCC1442.02 Antibody has been specifically validated for Enzyme-Linked Immunosorbent Assay (ELISA) and Western Blot (WB) applications. These validated applications provide researchers with reliable methods for detecting and quantifying the SPCC1442.02 protein in experimental samples .

The antibody's application in other techniques such as immunohistochemistry, immunoprecipitation, or flow cytometry would require additional validation by researchers. When designing an experimental protocol, researchers should consider that the antibody's performance may vary depending on the specific experimental conditions, sample preparation methods, and detection systems employed.

What protocol modifications are necessary when using SPCC1442.02 Antibody for Western Blot analysis?

When using SPCC1442.02 Antibody for Western Blot analysis, researchers should consider the following optimized protocol:

• Sample Preparation: Extract proteins from S. pombe cells using a yeast-specific lysis buffer containing protease inhibitors to prevent protein degradation.

• Protein Separation: Separate proteins using SDS-PAGE with appropriate percentage gels (typically 10-12% for medium-sized proteins).

• Transfer Conditions: Use wet transfer with PVDF membranes (0.45 μm pore size) at 100V for 60-90 minutes in cold transfer buffer.

• Blocking Conditions: Block membranes with 5% non-fat dry milk in TBST for 1 hour at room temperature.

• Primary Antibody Incubation: Dilute SPCC1442.02 Antibody to 1:500-1:2000 in blocking buffer and incubate overnight at 4°C with gentle agitation.

• Secondary Antibody: Use anti-rabbit HRP-conjugated secondary antibody at 1:5000-1:10000 dilution for 1 hour at room temperature.

• Detection: Employ enhanced chemiluminescence (ECL) detection methods with appropriate exposure times.

This protocol should be optimized based on protein expression levels, with careful attention to washing steps (3-5 washes of 5-10 minutes each with TBST) to minimize background signal .

How can researchers validate SPCC1442.02 Antibody specificity to avoid false positives?

Validating antibody specificity is critical for obtaining reliable results. For SPCC1442.02 Antibody, researchers should implement a multi-faceted validation approach:

• Knockout/Knockdown Controls: Use SPCC1442.02 deletion strains or RNAi-mediated knockdown samples as negative controls to confirm signal specificity.

• Overexpression Analysis: Compare signal intensity between wild-type and SPCC1442.02-overexpressing strains to confirm proportional signal increase.

• Peptide Competition Assay: Pre-incubate the antibody with excess SPCC1442.02 recombinant protein before application to samples. Signal reduction indicates specificity.

• Cross-Reactivity Testing: Test the antibody against lysates from other yeast species to evaluate potential cross-reactivity.

• PolySpecificity Assessment: Consider employing the PolySpecificity Particle (PSP) assay to evaluate potential nonspecific interactions, which provides higher sensitivity than standard ELISA methods for detecting antibody polyreactivity .

A comprehensive validation should include both positive and negative controls under standardized experimental conditions to establish reproducible specificity profiles.

What are the critical factors affecting SPCC1442.02 Antibody sensitivity in experimental applications?

Several factors can significantly impact SPCC1442.02 Antibody sensitivity:

Research has demonstrated that antibody performance can be dramatically affected by sample preparation methods, particularly for yeast proteins, which require specialized extraction protocols to break down the rigid cell wall structure .

How can researchers minimize nonspecific interactions when using SPCC1442.02 Antibody?

Nonspecific interactions can compromise experimental results. To minimize these interactions when using SPCC1442.02 Antibody:

• Blocking Optimization: Test different blocking agents (BSA, casein, non-fat dry milk) at various concentrations (1-5%) to determine which most effectively reduces background.

• Detergent Adjustment: Optimize Tween-20 or Triton X-100 concentration (0.05-0.3%) in washing and antibody dilution buffers.

• Cross-Adsorption: Consider pre-adsorbing the antibody with lysates from related species to remove cross-reactive antibodies.

• Buffer Salt Concentration: Adjust salt concentration (150-500 mM NaCl) to reduce electrostatic nonspecific interactions.

• Implement PSP Assay: The PolySpecificity Particle assay can be used to assess antibody nonspecific interactions with high sensitivity, requiring only 0.1-4 μg of antibody for triplicate measurements .

The PSP assay has demonstrated superior sensitivity compared to traditional ELISA methods for detecting antibody polyspecificity, enabling researchers to identify potential nonspecific interactions before they compromise experimental results .

How can SPCC1442.02 Antibody be adapted for yeast surface display techniques?

Adapting SPCC1442.02 Antibody for yeast surface display involves a specialized methodology:

• Protein A Display System: Utilize a system similar to that described for non-covalent antibody linking, where Staphylococcal protein A is expressed on the yeast surface using a secretion signal (e.g., from Rhizopus oryzae glucoamylase) and a C-terminal GPI anchor attachment signal .

• Antibody Capture: The displayed Protein A can capture the Fc region of SPCC1442.02 Antibody, effectively displaying it on the yeast surface .

• Expression Vector Design: Design expression vectors containing the necessary components:

  • GAPDH promoter for Protein A expression

  • Appropriate secretion signals

  • GPI anchor attachment signals for surface display

  • Selection markers for stable transformation

• Verification Methods: Confirm successful display using immunofluorescence microscopy with anti-rabbit secondary antibodies conjugated to fluorescent markers .

This "secretion-and-capture" strategy leverages the natural affinity between Protein A and antibody Fc regions, providing a flexible platform for antibody display without genetic fusion requirements .

What methods are recommended for quantifying SPCC1442.02 protein expression using the antibody?

For quantitative analysis of SPCC1442.02 protein expression, researchers should consider these advanced methodological approaches:

• Quantitative Western Blotting:

  • Use purified recombinant SPCC1442.02 protein to create a standard curve

  • Employ digital imaging systems rather than film exposure

  • Implement fluorescent secondary antibodies for more precise quantification

  • Analyze band intensity using specialized software with appropriate background correction

• Quantitative ELISA Development:

  • Establish a sandwich ELISA using SPCC1442.02 Antibody as the capture antibody

  • Consider biotinylation of detection antibodies to enhance sensitivity

  • Implement 4-parameter logistic regression for standard curve analysis

• Flow Cytometry Quantification:

  • Permeabilize fixed yeast cells for intracellular protein detection

  • Use fluorophore-conjugated secondary antibodies

  • Include calibration beads with known antibody binding capacity

  • Calculate molecules of equivalent soluble fluorochrome (MESF) values

Each quantification method requires appropriate controls, including isotype controls, blocking peptide controls, and samples from knockout strains to verify specificity and establish baseline measurements .

How can SPCC1442.02 Antibody be employed for protein-protein interaction studies?

For investigating protein-protein interactions involving SPCC1442.02, researchers can utilize several advanced approaches:

• Co-Immunoprecipitation (Co-IP):

  • Use SPCC1442.02 Antibody conjugated to protein G agarose or magnetic beads

  • Optimize lysis conditions to preserve protein-protein interactions

  • Include appropriate negative controls (IgG from non-immunized rabbits)

  • Verify precipitated complexes using antibodies against suspected interaction partners

• Proximity Ligation Assay (PLA):

  • Combine SPCC1442.02 Antibody with antibodies against potential interaction partners

  • Use species-specific secondary antibodies with oligonucleotide probes

  • Optimize fixation and permeabilization for yeast cells

  • Quantify interaction signals using confocal microscopy

• FRET-based Interaction Analysis:

  • Label SPCC1442.02 Antibody with donor fluorophores

  • Label partner protein antibodies with acceptor fluorophores

  • Measure energy transfer as evidence of protein proximity

  • Calculate FRET efficiency to estimate interaction strength

These methodologies require careful optimization of antibody concentrations and incubation conditions to maximize specific interactions while minimizing background signals. Researchers should validate each approach using known interaction partners before investigating novel interactions .

What considerations are important when applying SPCC1442.02 Antibody in chromatin immunoprecipitation studies?

When using SPCC1442.02 Antibody for chromatin immunoprecipitation (ChIP) studies, researchers should address these critical methodological considerations:

• Crosslinking Optimization:

  • Test different formaldehyde concentrations (0.5-3%) and incubation times

  • Consider dual crosslinking with protein-specific crosslinkers if the target has indirect DNA interactions

  • Optimize quenching conditions to prevent over-crosslinking

• Chromatin Fragmentation:

  • Adjust sonication parameters specifically for S. pombe cells

  • Verify fragment size distribution (200-500 bp optimal) by agarose gel electrophoresis

  • Consider enzymatic fragmentation alternatives if sonication proves inconsistent

• Antibody Validation for ChIP:

  • Perform preliminary IP experiments to confirm the antibody can recognize crosslinked protein

  • Include mock IP controls (no antibody) and IgG controls

  • Validate enrichment at known binding sites before genome-wide studies

• Data Analysis Considerations:

  • Normalize enrichment to input samples

  • Implement appropriate peak calling algorithms

  • Validate peaks with orthogonal techniques (e.g., reporter assays)

ChIP applications typically require larger amounts of antibody than standard immunoprecipitation protocols, so researchers should optimize antibody concentration to achieve maximum chromatin recovery while minimizing background .

How does SPCC1442.02 Antibody performance compare to other antibodies targeting S. pombe proteins?

When evaluating comparative performance metrics for fission yeast antibodies, researchers should consider:

Researchers have observed that antibody performance in yeast systems often requires specialized protocols due to the unique cell wall composition and protein modification patterns in fungi. The ability to detect native versus denatured protein conformations should be considered when selecting antibodies for specific applications .

What emerging methodologies might enhance SPCC1442.02 Antibody utility in future research?

Several emerging technologies show promise for expanding SPCC1442.02 Antibody applications:

• Nanobody Development: Converting conventional antibodies to smaller nanobody formats could enhance penetration in intact yeast cells and reduce nonspecific binding.

• Antibody Fragment Display Systems: Adaptation of the "secretion-and-capture" yeast display technology for Fab or scFv fragments derived from SPCC1442.02 Antibody could enable novel screening applications .

• Single-Cell Antibody-Based Proteomics: Integration with mass cytometry (CyTOF) or microfluidic platforms for analyzing SPCC1442.02 expression at the single-cell level.

• Antibody-Drug Conjugates for Targeted Protein Degradation: Though primarily developed for therapeutic applications, these technologies could be adapted for selective protein degradation in research contexts.

• PolySpecificity Assessment Platforms: Implementation of the PSP assay for routine antibody quality control could significantly improve experimental reproducibility by identifying antibodies with potential for nonspecific interactions before use in critical experiments .

The development of these methodologies could address current limitations in yeast protein detection and quantification, particularly for proteins with low abundance or in specialized subcellular compartments.